Aktiesnakken — Juli 2012
-
hvem kommer først med salgstallene
-
salg up 35%¡
-
H1 2012 (£375 million; +22%)
Growth in the category in the half year was driven by new products Votrient (up 87% to £72 million),
Promacta (up 97% to £57 million) and Arzerra (up 35% to £27 million). Hycamtin sales fell 26% to
£20 million as a result of generic competition in Europe. -
q1 er faktisk bedre 15 mill
¨ -
nej helt sikkert ikke. Alle er bare på ferie
-
vi sidder iøvrigt i genmab gruppen
-
-
Caterpillar opjusterer sine forventninger til hele årets indtjening efter et lovende andet kvartal.
Forven
tningerne til 2012 lyder nu på en indtjening per aktie på 9,60 dollar. Tidligere ventede Caterpillar 9,50 dollar per aktie. -
9,6 per aktie .... vildt er det for kvartalet?
-
9,60 er for helåret..
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind